Clinical trial
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant…
NCT00339586 · AZ-VUB, Other · Unknown status
Key facts
| NCT number | NCT00339586 |
|---|---|
| Title | First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene |
| Official title | Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene |
| Lead sponsor | AZ-VUB, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms, Non-Small Cell Lung Cancer, Adenocarcinoma, Bronchiolo-Alveolar |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 40 |
| Start date | Jan 1, 2006 |
| First posted | Jun 21, 2006 |
| Last update posted | Jun 21, 2006 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: